KRAS and cholangiocarcinoma: In genomic and transcriptomic analyses of 133 cHCC-CCA cases, combined type cHCC-CCAs showed strong iCCA-like features, including higher expression of EpCAM, CK19, and PRDM5, and enrichment of KRAS mutations and higher expression of KRAS [51].